Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MDGLthis companyMadrigal Pharmaceuticals, Inc.	$426.12	-45.32×	21.68×	13.63×	-49.99×	476.6%	94.1%	-31.3%	-30.1%	-47.8%	-31.6%	-1.5%	0.59×	-0.59×	-13.45×	4.01×	0.0%	2	6.8	2	C
ALTAltimmune, Inc.	$2.18	-3.61×	1.41×	7,757.46×	-3.56×	-96.0%	100.0%	-230461.0%	-214861.0%	-39.2%	-35.4%	-21.2%	0.16×	0.09×	-57.76×	18.55×	0.0%	2	2.76	2	C+
MAZEMaze Therapeutics, Inc.	$34.30	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
SGMTSagimet Biosciences Inc.	$10.55	-3.75×	1.72×	0×	-3.07×	-89.2%	0.0%	0.0%	0.0%	-45.8%	-51.0%	-23.8%	0×	0.68×	0×	22.82×	0.0%	2	24.53	2	C+
VKTXViking Therapeutics, Inc.	$28.33	-11.03×	6.2×	0×	-10.57×	-96.2%	0.0%	0.0%	0.0%	-56.3%	-61.5%	-7.0%	0×	0.46×	0×	9.33×	0.0%	1	2.31	1	C-
Peer median	—	-7.39×	3.37×	0×	-7.07×	-92.6%	0.0%	0.0%	0.0%	-42.5%	-44.4%	-14.1%	0.03×	0.57×	0×	17.03×	0.0%	2	7.15	2	—